Abstract
The relationship between inflammation and cancer has been long recognized by the medical and scientific community. In the last decades, it has returned to the forefront of clinical oncology since a wealth of knowledge has been gathered about the cells, cytokines and physiological processes that are central to both inflammation and cancer. It is now robustly established that chronic inflammation can induce certain cancers but also that solid tumors, in turn, can initiate and perpetuate local inflammatory processes that foster tumor growth and dissemination. Inflammation is the hallmark of the innate immune response to tissue damage or infection, but also mediates the activation, expansion and recruitment to the tissues of cells and antibodies of the adaptive immune system. The functional integration of both components of the immune response is crucial to identify and subdue tumor development, progression and dissemination. When this tight control goes awry, altered cells can avoid the immune surveillance and even subvert the innate immunity to promote their full oncogenic transformation. In this chapter, we make a general overview of the most recent data linking the inflammatory process to cancer. We start with the overall inflammatory cues and processes that influence the relationship between tumor and the microenvironment that surrounds it and follow the ever-increasing complexity of processes that end up producing subtle changes in the splicing of certain genes to ascertain survival advantage to cancer cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adegboyega PA, Ololade O, Saada J, Mifflin R, Di Mari JF, Powell DW (2004) Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res Off J Am Assoc Cancer Res 10:5870–5879. https://doi.org/10.1158/1078-0432.CCR-0431-03
Agrawal AA, Yu L, Smith PG, Buonamici S (2018) Targeting splicing abnormalities in cancer. Curr Opin Genet Dev 48:67–74. https://doi.org/10.1016/j.gde.2017.10.010
Anil C, Goksel S, Gursoy A (2010) Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid Off J Am Thyroid Assoc 20:601–606. https://doi.org/10.1089/thy.2009.0450
Bellahcène A, Castronovo V, Ogbureke KUE, Fisher LW, Fedarko NS (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8:212–226. https://doi.org/10.1038/nrc2345
Boi F, Pani F, Mariotti S (2017) Thyroid autoimmunity and thyroid cancer: review focused on cytological studies. Eur Thyroid J 6:178–186. https://doi.org/10.1159/000468928
Briones-Orta MA, Avendaño-Vázquez SE, Aparicio-Bautista DI, Coombes JD, Weber GF, Syn W-K (2017) Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim Biophys Acta BBA – Rev Cancer 1868:93–108. https://doi.org/10.1016/j.bbcan.2017.02.005
Brosseau J-P, Lucier J-F, Nwilati H, Thibault P, Garneau D, Gendron D, Durand M, Couture S, Lapointe E, Prinos P, Klinck R, Perreault J-P, Chabot B, Abou-Elela S (2014) Tumor microenvironment-associated modifications of alternative splicing. RNA 20:189–201. https://doi.org/10.1261/rna.042168.113
Castagna MG, Belardini V, Memmo S, Maino F, Di Santo A, Toti P, Carli AF, Caruso G, Pacini F (2014) Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias. J Clin Endocrinol Metab 99:3193–3198. https://doi.org/10.1210/jc.2014-1302
Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, Garzaro M, Gentilli S, Navalesi P, Cantaluppi V, Dianzani U, Aspesi A, Chiocchetti A (2017) Osteopontin at the crossroads of inflammation and tumor progression. Mediat Inflamm 2017:1–22. https://doi.org/10.1155/2017/4049098
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310:1504–1510. https://doi.org/10.1126/science.1116221
Chen M, Zhang J, Manley JL (2010) Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res 70:8977–8980. https://doi.org/10.1158/0008-5472.CAN-10-2513
Cheng C, Yaffe MB, Sharp PA (2006) A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 20:1715–1720. https://doi.org/10.1101/gad.1430906
Climente-González H, Porta-Pardo E, Godzik A, Eyras E (2017) The functional impact of alternative splicing in cancer. Cell Rep 20:2215–2226. https://doi.org/10.1016/j.celrep.2017.08.012
Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR (2010) The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A 107:1894–1899. https://doi.org/10.1073/pnas.0914845107
Correa P (1995) Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 19(Suppl 1):S37–S43
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867. https://doi.org/10.1038/nature01322
Dailey ME, Lindsay S, Skahen R (1955) Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70:291–297
David CJ, Chen M, Assanah M, Canoll P, Manley JL (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463:364–368. https://doi.org/10.1038/nature08697
Dery KJ, Kujawski M, Grunert D, Wu X, Ngyuen T, Cheung C, Yim JH, Shively JE (2014) IRF-1 regulates alternative mRNA splicing of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in breast epithelial cells generating an immunoreceptor tyrosine-based inhibition motif (ITIM) containing isoform. Mol Cancer 13:64. https://doi.org/10.1186/1476-4598-13-64
Devaud C, Tilkin-Mariamé A-F, Vignolle-Vidoni A, Souleres P, Denadai-Souza A, Rolland C, Duthoit C, Blanpied C, Chabot S, Bouillé P, Lluel P, Vergnolle N, Racaud-Sultan C, Ferrand A (2019) FAK alternative splice mRNA variants expression pattern in colorectal cancer: FAK alternative splice mRNA variants expression pattern in colorectal cancer. Int J Cancer. https://doi.org/10.1002/ijc.32120
Dong YH, Fu DG (2014) Autoimmune thyroid disease: mechanism, genetics and current knowledge. Eur Rev Med Pharmacol Sci 18:3611–3618
Dvinge H (2018) Regulation of alternative mRNA splicing: old players and new perspectives. FEBS Lett 592:2987–3006. https://doi.org/10.1002/1873-3468.13119
Faria M, Capinha L, Simões-Pereira J, Bugalho MJ, Silva AL (2016) Extending the impact of RAC1b overexpression to follicular thyroid carcinomas. Int J Endocrinol 2016:1972367. https://doi.org/10.1155/2016/1972367
Faria M, Matos P, Pereira T, Cabrera R, Cardoso BA, Bugalho MJ, Silva AL (2017) RAC1b overexpression stimulates proliferation and NF-kB-mediated anti-apoptotic signaling in thyroid cancer cells. PLoS One 12:e0172689. https://doi.org/10.1371/journal.pone.0172689
Ferreira LB, Tavares C, Pestana A, Pereira CL, Eloy C, Pinto MT, Castro P, Batista R, Rios E, Sobrinho-Simões M, Gimba ERP, Soares P (2016) Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget 7. https://doi.org/10.18632/oncotarget.10468
Fiegen D, Haeusler L-C, Blumenstein L, Herbrand U, Dvorsky R, Vetter IR, Ahmadian MR (2004) Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase. J Biol Chem 279:4743–4749. https://doi.org/10.1074/jbc.M310281200
Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1:55–67. https://doi.org/10.1038/35094067
Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7:1016–1036
Fugazzola L, Colombo C, Perrino M, Muzza M (2011) Papillary thyroid carcinoma and inflammation. Front Endocrinol 2. https://doi.org/10.3389/fendo.2011.00088
Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol Orlando Fla 102:169–178. https://doi.org/10.1006/clim.2001.5163
Georgilis A, Klotz S, Hanley CJ, Herranz N, Weirich B, Morancho B, Leote AC, D’Artista L, Gallage S, Seehawer M, Carroll T, Dharmalingam G, Wee KB, Mellone M, Pombo J, Heide D, Guccione E, Arribas J, Barbosa-Morais NL, Heikenwalder M, Thomas GJ, Zender L, Gil J (2018) PTBP1-mediated alternative splicing regulates the inflammatory Secretome and the pro-tumorigenic effects of senescent cells. Cancer Cell 34:85–102.e9. https://doi.org/10.1016/j.ccell.2018.06.007
Gimba ER, Tilli TM (2013) Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett 331:11–17. https://doi.org/10.1016/j.canlet.2012.12.003
Giorgio M, Maria Z, Maria C, Marco I, Martina S, Gianna F, Eliana C, Giovanna R (2013) Pro-inflammatory cytokines analysis in HPV-positive cancer cells. Front Immunol 4. https://doi.org/10.3389/conf.fimmu.2013.02.00306
Gomaa W, Al-Ahwal M, Hamour O, Al-Maghrabi J (2013) Osteopontin cytoplasmic immunoexpression is a predictor of poor disease-free survival in thyroid cancer. J Microsc Ultrastruct 1:8. https://doi.org/10.1016/j.jmau.2013.07.001
Gonçalves V, Matos P, Jordan P (2009) Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum Mol Genet 18:3696–3707. https://doi.org/10.1093/hmg/ddp317
Gonçalves V, Henriques AFA, Henriques A, Pereira JFS, Pereira J, Neves Costa A, Moyer MP, Moita LF, Gama-Carvalho M, Matos P, Jordan P (2014) Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells. RNA 20:474–482. https://doi.org/10.1261/rna.041376.113
Gonçalves V, Pereira J, Jordan P (2017) Signaling pathways driving aberrant splicing in cancer cells. Genes 9:9. https://doi.org/10.3390/genes9010009
Gonzalez-Zubeldia I, Dotor J, Redrado M, Bleau A-M, Manrique I, de Aberasturi AL, Villalba M, Calvo A (2015) Co-migration of colon cancer cells and CAFs induced by TGFβ1 enhances liver metastasis. Cell Tissue Res 359:829–839. https://doi.org/10.1007/s00441-014-2075-6
Grivennikov SI (2013) Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 35:229–244. https://doi.org/10.1007/s00281-012-0352-6
Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103–113. https://doi.org/10.1016/j.ccr.2009.01.001
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899. https://doi.org/10.1016/j.cell.2010.01.025
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hassuneh MR, Nagarkatti M, Nagarkatti PS (2013) Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma. Leuk Lymphoma 54:827–834. https://doi.org/10.3109/10428194.2012.726721
Hayes GM, Carrigan PE, Miller LJ (2007) Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 67:2072–2080. https://doi.org/10.1158/0008-5472.CAN-06-2969
Herbeuval J-P, Lelievre E, Lambert C, Dy M, Genin C (2004) Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol Baltim Md 172:4630–4636
Hermiston ML, Xu Z, Weiss A (2003) CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21:107–137. https://doi.org/10.1146/annurev.immunol.21.120601.140946
Hollander D, Donyo M, Atias N, Mekahel K, Melamed Z, Yannai S, Lev-Maor G, Shilo A, Schwartz S, Barshack I, Sharan R, Ast G (2016) A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. Genome Res 26:541–553. https://doi.org/10.1101/gr.193169.115
Jankovic B, Le KT, Hershman JM (2013) Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 98:474–482. https://doi.org/10.1210/jc.2012-2978
Jedinak A, Dudhgaonkar S, Sliva D (2010) Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 215:242–249. https://doi.org/10.1016/j.imbio.2009.03.004
Jordan P, Brazåo R, Boavida MG, Gespach C, Chastre E (1999) Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 18:6835–6839. https://doi.org/10.1038/sj.onc.1203233
Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239–252. https://doi.org/10.1038/nrc2618
Kaler P, Godasi BN, Augenlicht L, Klampfer L (2009) The NF-κB/AKT-dependent induction of Wnt signaling in colon cancer cells by macrophages and IL-1β. Cancer Microenviron Off J Int Cancer Microenviron Soc 2:69–80. https://doi.org/10.1007/s12307-009-0030-y
Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M (2019) Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci 20. https://doi.org/10.3390/ijms20061358
Kazanecki CC, Uzwiak DJ, Denhardt DT (2007) Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102:912–924. https://doi.org/10.1002/jcb.21558
Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52–67. https://doi.org/10.1016/j.cell.2010.03.015
Kim S, Myong JP, Jee H-G, Chai YJ, Choi JY, Min HS, Lee KE, Youn Y-K (2016) Combined effect of Hashimoto’s thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer. Head Neck 38:95–101. https://doi.org/10.1002/hed.23854
Kim WW, Ha TK, Bae SK (2018) Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. J Otolaryngol – Head Neck Surg 47. https://doi.org/10.1186/s40463-017-0247-6
Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Gervais-Bird J, Madden R, Paquet ER, Koh C, Venables JP, Prinos P, Jilaveanu-Pelmus M, Wellinger R, Rancourt C, Chabot B, Abou Elela S (2008) Multiple alternative splicing markers for ovarian cancer. Cancer Res 68:657–663. https://doi.org/10.1158/0008-5472.CAN-07-2580
Kumari S, Badana AK, MM G, S G, Malla R (2018) Reactive oxygen species: a key constituent in cancer survival. Biomark Insights 13:1177271918755391. https://doi.org/10.1177/1177271918755391
Lai X, Xia Y, Zhang B, Li J, Jiang Y (2017) A meta-analysis of Hashimoto’s thyroiditis and papillary thyroid carcinoma risk. Oncotarget 8:62414–62424. https://doi.org/10.18632/oncotarget.18620
Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185. https://doi.org/10.1155/2014/149185
Lee SC-W, Abdel-Wahab O (2016) Therapeutic targeting of splicing in cancer. Nat Med 22:976–986. https://doi.org/10.1038/nm.4165
Lee G, Goretsky T, Managlia E, Dirisina R, Singh AP, Brown JB, May R, Yang G-Y, Ragheb JW, Evers BM, Weber CR, Turner JR, He XC, Katzman RB, Li L, Barrett TA (2010) Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 139(869–881):881–889. https://doi.org/10.1053/j.gastro.2010.05.037
Li CY, Chu JY, Yu JK, Huang XQ, Liu XJ, Shi L, Che YC, Xie JY (2004) Regulation of alternative splicing of Bcl-x by IL-6, GM-CSF and TPA. Cell Res 14:473–479. https://doi.org/10.1038/sj.cr.7290250
Li H, Fan X, Houghton J (2007) Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 101:805–815. https://doi.org/10.1002/jcb.21159
Liang J, Zeng W, Fang F, Yu T, Zhao Y, Fan X, Guo N, Gao X (2017) Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients. Acta Otorhinolaryngol Ital Organo Uff Della Soc Ital Otorinolaringol E Chir Cerv-facc 37:393–400. https://doi.org/10.14639/0392-100X-1709
Likui W, Hong W, Shuwen Z (2010) Clinical significance of the upregulated Osteopontin mRNA expression in human colorectal Cancer. J Gastrointest Surg 14:74–81. https://doi.org/10.1007/s11605-009-1035-z
Liu S, Cheng C (2013) Alternative RNA splicing and cancer: alternative RNA splicing and cancer. Wiley Interdiscip Rev RNA 4:547–566. https://doi.org/10.1002/wrna.1178
Liu J, Li H, Shen S, Sun L, Yuan Y, Xing C (2018) Alternative splicing events implicated in carcinogenesis and prognosis of colorectal cancer. J Cancer 9:1754–1764. https://doi.org/10.7150/jca.24569
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. https://doi.org/10.1038/nature07205
Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ (2017) Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci 18. https://doi.org/10.3390/ijms18010197
Matos P, Jordan P (2005) Expression of Rac1b stimulates NF-kappaB-mediated cell survival and G1/S progression. Exp Cell Res 305:292–299. https://doi.org/10.1016/j.yexcr.2004.12.029
Matos P, Jordan P (2006) Rac1, but not Rac1B, stimulates RelB-mediated gene transcription in colorectal cancer cells. J Biol Chem 281:13724–13732. https://doi.org/10.1074/jbc.M513243200
Matos P, Jordan P (2008) Increased Rac1b expression sustains colorectal tumor cell survival. Mol Cancer Res MCR 6:1178–1184. https://doi.org/10.1158/1541-7786.MCR-08-0008
Matos P, Jordan P (2015) Beyond COX-inhibition: “side-effects” of ibuprofen on neoplastic development and progression. Curr Pharm Des 21:2978–2982
Matos P, Collard JG, Jordan P (2003) Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling. J Biol Chem 278:50442–50448. https://doi.org/10.1074/jbc.M308215200
Matos P, Oliveira C, Velho S, Gonçalves V, da Costa LT, Moyer MP, Seruca R, Jordan P (2008) B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. Gastroenterology 135:899–906. https://doi.org/10.1053/j.gastro.2008.05.052
Matos P, Kotelevets L, Jordan P, Gonçalves V, Henriques A, Zerbib P, Moyer MP, Chastre E (2013) Ibuprofen inhibits colitis-induced overexpression of tumor related Rac1b. Neoplasia 15:102–111. https://doi.org/10.1593/neo.121890
Matos P, Gonçalves V, Jordan P (2016) Targeting the serrated pathway of colorectal cancer with mutation in BRAF. Biochim Biophys Acta 1866:51–63. https://doi.org/10.1016/j.bbcan.2016.06.003
Mehner C, Miller E, Nassar A, Bamlet WR, Radisky ES, Radisky DC (2015) Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer 6:480–489. https://doi.org/10.18632/genesandcancer.90
Melzer C, Hass R, Lehnert H, Ungefroren H (2019) RAC1B: a Rho GTPase with versatile functions in malignant transformation and tumor progression. Cell 8. https://doi.org/10.3390/cells8010021
Muñoz Ú, Puche JE, Hannivoort R, Lang UE, Cohen-Naftaly M, Friedman SL (2012) Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol Cancer Res MCR 10:1216–1227. https://doi.org/10.1158/1541-7786.MCR-12-0213
Muzza M, Degl’Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG, Fugazzola L (2010) The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol 72:702–708. https://doi.org/10.1111/j.1365-2265.2009.03699.x
Nagayama Y (2018) Thyroid autoimmunity and thyroid cancer – the pathogenic connection: a 2018 update. Horm Metab Res Horm Stoffwechselforschung Horm Metab 50:922–931. https://doi.org/10.1055/a-0648-4593
Nakamura K, Smyth MJ (2017) Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol 95:325–332. https://doi.org/10.1038/icb.2016.126
Oberdoerffer S, Moita LF, Neems D, Freitas RP, Hacohen N, Rao A (2008) Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPLL. Science 321:686–691. https://doi.org/10.1126/science.1157610
Oh C-M, Park S, Lee JY, Won Y-J, Shin A, Kong H-J, Choi K-S, Lee YJ, Chung K-W, Jung K-W (2014) Increased prevalence of chronic lymphocytic thyroiditis in Korean patients with papillary thyroid cancer. PLoS One 9:e99054. https://doi.org/10.1371/journal.pone.0099054
Parascandolo A, Rappa F, Cappello F, Kim J, Cantu DA, Chen H, Mazzoccoli G, Hematti P, Castellone MD, Salvatore M, Laukkanen MO (2017) Extracellular superoxide dismutase expression in papillary thyroid cancer mesenchymal stem/stromal cells modulates cancer cell growth and migration. Sci Rep 7:41416. https://doi.org/10.1038/srep41416
Pelisch F, Khauv D, Risso G, Stallings-Mann M, Blaustein M, Quadrana L, Radisky DC, Srebrow A (2012) Involvement of hnRNP A1 in the matrix metalloprotease-3-dependent regulation of Rac1 pre-mRNA splicing. J Cell Biochem 113:2319–2329. https://doi.org/10.1002/jcb.24103
Picon A, Gold LI, Wang J, Cohen A, Friedman E (1998) A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 7:497–504
Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM, Morrow JD, Capdevila JH (2004) Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 279:29797–29804. https://doi.org/10.1074/jbc.M313989200
Prochazka L, Tesarik R, Turanek J (2014) Regulation of alternative splicing of CD44 in cancer. Cell Signal 26:2234–2239. https://doi.org/10.1016/j.cellsig.2014.07.011
Radisky ES, Radisky DC (2015) Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci Landmark Ed 20:1144–1163
Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436:123–127. https://doi.org/10.1038/nature03688
Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79–87. https://doi.org/10.1016/j.tcb.2005.12.005
Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J (2014) Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 5:75. https://doi.org/10.3389/fphys.2014.00075
Romano M, DE Francesco F, Zarantonello L, Ruffolo C, Ferraro GA, Zanus G, Giordano A, Bassi N, Cillo U (2016) From inflammation to Cancer in inflammatory bowel disease: molecular perspectives. Anticancer Res 36:1447–1460
Roque AT, Gambeloni RZ, Felitti S, Ribeiro ML, Santos JC (2015) Inflammation-induced oxidative stress in breast cancer patients. Med Oncol Northwood Lond Engl 32:263. https://doi.org/10.1007/s12032-015-0709-5
Ryder M, Ghossein RA, Ricarte-Filho JCM, Knauf JA, Fagin JA (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15:1069–1074. https://doi.org/10.1677/ERC-08-0036
Sanford JR (2004) Pre-mRNA splicing: life at the centre of the central dogma. J Cell Sci 117:6261–6263. https://doi.org/10.1242/jcs.01513
Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161:947–956. https://doi.org/10.1016/S0002-9440(10)64255-1
Selek A, Cetinarslan B, Tarkun I, Canturk Z, Ustuner B, Akyay Z (2017) Thyroid autoimmunity: is really associated with papillary thyroid carcinoma? Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol – Head Neck Surg 274:1677–1681. https://doi.org/10.1007/s00405-016-4414-6
Senbanjo LT, Chellaiah MA (2017) CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of Cancer cells. Front Cell Dev Biol 5. https://doi.org/10.3389/fcell.2017.00018
Shilo A, Ben Hur V, Denichenko P, Stein I, Pikarsky E, Rauch J, Kolch W, Zender L, Karni R (2014) Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling a-Raf splicing in hepatocellular carcinoma development. RNA 20:505–515. https://doi.org/10.1261/rna.042259.113
Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, Hawkins AJ, Shay JW, Minna JD, Chalfant CE (2010) Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res 70:9185–9196. https://doi.org/10.1158/0008-5472.CAN-10-1545
Silva AL, Carmo F, Bugalho MJ (2013) RAC1b overexpression in papillary thyroid carcinoma: a role to unravel. Eur J Endocrinol Eur Fed Endocr Soc 168:795–804. https://doi.org/10.1530/EJE-12-0960
Song E, Jeon MJ, Park S, Kim M, Oh H-S, Song DE, Kim WG, Kim WB, Shong YK, Kim TY (2018a) Influence of coexistent Hashimoto’s thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma. Clin Endocrinol 88:123–128. https://doi.org/10.1111/cen.13475
Song X, Zeng Z, Wei H, Wang Z (2018b) Alternative splicing in cancers: from aberrant regulation to new therapeutics. Semin Cell Dev Biol 75:13–22. https://doi.org/10.1016/j.semcdb.2017.09.018
Stallings-Mann ML, Waldmann J, Zhang Y, Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields AP, Radisky DC (2012) Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl med 4:142ra95. https://doi.org/10.1126/scitranslmed.3004062
Sun D, Novotny M, Bulek K, Liu C, Li X, Hamilton T (2011) Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol 12:853–860. https://doi.org/10.1038/ni.2081
Takahashi H, Nishimura J, Kagawa Y, Kano Y, Takahashi Y, Wu X, Hiraki M, Hamabe A, Konno M, Haraguchi N, Takemasa I, Mizushima T, Ishii M, Mimori K, Ishii H, Doki Y, Mori M, Yamamoto H (2015) Significance of polypyrimidine tract-binding protein 1 expression in colorectal cancer. Mol Cancer Ther 14:1705–1716. https://doi.org/10.1158/1535-7163.MCT-14-0142
Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Matsuhashi N, Futamura M, Ito Y, Otsuki Y, Yoshida K, Uchiyama K, Akao Y (2015) Positive feedback of DDX6/c-Myc/PTB1 regulated by miR-124 contributes to maintenance of the Warburg effect in colon cancer cells. Biochim Biophys Acta 1852:1971–1980. https://doi.org/10.1016/j.bbadis.2015.06.022
Tauler J, Mulshine JL (2009) Lung cancer and inflammation: interaction of chemokines and hnRNPs. Curr Opin Pharmacol 9:384–388. https://doi.org/10.1016/j.coph.2009.06.004
Tessner TG, Muhale F, Riehl TE, Anant S, Stenson WF (2004) Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 114:1676–1685. https://doi.org/10.1172/JCI22218
Tilli TM, Franco VF, Robbs BK, Wanderley JLM, de Azevedo da Silva FR, de Mello KD, Viola JPB, Weber GF, Gimba ER (2011) Osteopontin-c splicing isoform contributes to ovarian Cancer progression. Mol Cancer Res 9:280–293. https://doi.org/10.1158/1541-7786.MCR-10-0463
Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R, Stassi G (2014) CD44v6 is a marker of constitutive and reprogrammed Cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14:342–356. https://doi.org/10.1016/j.stem.2014.01.009
Urbanski LM, Leclair N, Anczuków O (2018) Alternative-splicing defects in cancer: splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley Interdiscip Rev RNA 9:e1476. https://doi.org/10.1002/wrna.1476
Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, Durand M, Couture S, Froehlich U, Lapointe E, Lucier J-F, Thibault P, Rancourt C, Tremblay K, Prinos P, Chabot B, Elela SA (2009) Cancer-associated regulation of alternative splicing. Nat Struct Amp Mol Biol 16:670
Villalba M, Evans SR, Vidal-Vanaclocha F, Calvo A (2017) Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy. Cell Tissue Res 370:29–39. https://doi.org/10.1007/s00441-017-2633-9
Wai PY, Kuo PC (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27:103–118. https://doi.org/10.1007/s10555-007-9104-9
Wakefield LM, Hill CS (2013) Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat Rev Cancer 13:328–341. https://doi.org/10.1038/nrc3500
Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta BBA – Rev Cancer 1552:61–85. https://doi.org/10.1016/S0304-419X(01)00037-3
Xu Z, Weiss A (2002) Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat Immunol 3:764–771. https://doi.org/10.1038/ni822
Xu X, Wei Y, Wang S, Luo M, Zeng H (2017) Serine-arginine protein kinase 1 (SRPK1) is elevated in gastric cancer and plays oncogenic functions. Oncotarget 8:61944–61957. https://doi.org/10.18632/oncotarget.18734
Xue Y, Zhou Y, Wu T, Zhu T, Ji X, Kwon Y-S, Zhang C, Yeo G, Black DL, Sun H, Fu X-D, Zhang Y (2009) Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell 36:996–1006. https://doi.org/10.1016/j.molcel.2009.12.003
Zhou C, Licciulli S, Avila JL, Cho M, Troutman S, Jiang P, Kossenkov AV, Showe LC, Liu Q, Vachani A, Albelda SM, Kissil JL (2012a) The Rac1 splice form Rac1b promotes K-Ras-induced lung tumorigenesis. Oncogene. https://doi.org/10.1038/onc.2012.99
Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H, Hu Q, Ghosh G, Adams JA, Rosenfeld MG, Fu X-D (2012b) The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 47:422–433. https://doi.org/10.1016/j.molcel.2012.05.014
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Silva, A.L., Faria, M., Matos, P. (2020). Inflammatory Microenvironment Modulation of Alternative Splicing in Cancer: A Way to Adapt. In: Serpa, J. (eds) Tumor Microenvironment . Advances in Experimental Medicine and Biology, vol 1219. Springer, Cham. https://doi.org/10.1007/978-3-030-34025-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-030-34025-4_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-34024-7
Online ISBN: 978-3-030-34025-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)